Memo Therapeutics increases Series C financing to CHF 45 million [Yahoo! Finance]
Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) (FMS)
Last fresenius medical care ag american depositary shares (each representing 1/2 of an ordinary share) earnings: 7/31 04:03 pm
Check Earnings Report
US:NYSE Investor Relations:
freseniusmedicalcare.com/en/investors/investors-overview
Company Research
Source: Yahoo! Finance
Additional CHF 20 million raised from new investors Ysios Capital and Kurma Partners as well as from existing investors Proceeds will be used to expand Phase II of best-in-class anti-BK Virus antibody to become the largest study ever conducted for BK virus infection in kidney transplantation Schlieren / Zurich, Switzerland, 7 May, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, today announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million. The new funding will be used to bolster the clinical advancement of MTx's lead asset, AntiBKV, expanding the Phase II trial with a dose evaluation extension to be the largest BK viremia therapeutic study ever conducted in kidney transplant recipients. The disease represents a potential market in excess o
Show less
Read more
Impact Snapshot
Event Time:
FMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FMS alerts
High impacting Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) news events
Weekly update
A roundup of the hottest topics
FMS
News
- Renal Research Institute and Karolinska Institutet announce chronic kidney disease management symposium, highlighting new therapeutics [Yahoo! Finance]Yahoo! Finance
- American Oncology Network Appoints New Board Member [Yahoo! Finance]Yahoo! Finance
- Fresenius Medical Care Annual General Meeting: Company makes significant progress in its Transformation Efforts and confirms its ambitious 2024 Growth Targets [Yahoo! Finance]Yahoo! Finance
- Fresenius Medical Care Annual General Meeting: Company makes significant progress in its Transformation Efforts and confirms its ambitious 2024 Growth TargetsPR Newswire
- Fresenius Medical Care AG (NYSE: FMS) had its price target raised by analysts at Truist Financial Co. from $21.00 to $24.00. They now have a "hold" rating on the stock.MarketBeat
FMS
Earnings
- 8/3/23 - In-Line
FMS
Sec Filings
- 5/16/24 - Form 6-K
- 5/7/24 - Form 6-K
- 5/7/24 - Form 6-K
- FMS's page on the SEC website